Immuneering Co. (NASDAQ:IMRX) Expected to Announce Earnings of -$0.44 Per Share

Equities research analysts expect that Immuneering Co. (NASDAQ:IMRXGet Rating) will post ($0.44) earnings per share (EPS) for the current quarter, according to Zacks. Four analysts have issued estimates for Immuneering’s earnings. The lowest EPS estimate is ($0.46) and the highest is ($0.40). The company is scheduled to announce its next earnings report on Monday, January 1st.

On average, analysts expect that Immuneering will report full-year earnings of ($2.01) per share for the current year, with EPS estimates ranging from ($2.18) to ($1.74). For the next financial year, analysts expect that the business will post earnings of ($2.28) per share, with EPS estimates ranging from ($2.75) to ($1.90). Zacks Investment Research’s EPS averages are an average based on a survey of sell-side research analysts that follow Immuneering.

Immuneering (NASDAQ:IMRXGet Rating) last released its earnings results on Thursday, March 10th. The company reported ($0.42) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.39) by ($0.03). The business had revenue of $0.19 million for the quarter, compared to analyst estimates of $0.60 million.

Several analysts have recently commented on IMRX shares. Oppenheimer started coverage on shares of Immuneering in a research report on Thursday, March 31st. They set an “outperform” rating and a $25.00 price target on the stock. Zacks Investment Research raised shares of Immuneering from a “hold” rating to a “buy” rating and set a $4.75 price target on the stock in a research report on Wednesday. One investment analyst has rated the stock with a hold rating and six have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock has an average rating of “Buy” and a consensus target price of $29.13.

In related news, Director Ann E. Berman bought 6,000 shares of the company’s stock in a transaction that occurred on Tuesday, March 15th. The stock was purchased at an average price of $6.40 per share, for a total transaction of $38,400.00. The acquisition was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Insiders purchased a total of 9,900 shares of company stock valued at $69,201 in the last quarter.

Several large investors have recently bought and sold shares of IMRX. Citadel Advisors LLC acquired a new position in shares of Immuneering in the third quarter worth $52,403,000. BlackRock Inc. purchased a new stake in shares of Immuneering during the 3rd quarter worth $40,472,000. Rock Springs Capital Management LP purchased a new stake in shares of Immuneering during the 3rd quarter worth $28,935,000. Perceptive Advisors LLC purchased a new stake in Immuneering in the third quarter valued at $18,082,000. Finally, Adage Capital Partners GP L.L.C. purchased a new stake in Immuneering in the fourth quarter valued at $5,077,000. Institutional investors and hedge funds own 47.41% of the company’s stock.

IMRX opened at $4.89 on Wednesday. The company’s 50 day simple moving average is $6.49 and its two-hundred day simple moving average is $13.86. Immuneering has a 1-year low of $4.11 and a 1-year high of $33.99.

About Immuneering (Get Rating)

Immuneering Corporation, a biopharmaceutical company, focuses on the oncology and neuroscience product candidates. Its lead product candidates include IMM-1-104, a dual-MEK inhibitor to treat patients with cancer, including pancreatic, melanoma, colorectal, and non-small cell lung cancer caused by mutations of RAS and/or RAF; and IMM-6-415 to treat solid tumors.

Featured Articles

Get a free copy of the Zacks research report on Immuneering (IMRX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Immuneering (NASDAQ:IMRX)

Receive News & Ratings for Immuneering Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Immuneering and related companies with MarketBeat.com's FREE daily email newsletter.